FDA Seeking Info to Develop Guidances on Host Cell Protein Risk and Biosimilars

In its efforts to develop new guidances, the FDA is seeking information and comments on evaluating and mitigating the immunogenicity risk of host cell proteins (HCP) and the best way to advance development of new biosimilar biological products.
Source: Drug Industry Daily